Lack of an effect of pioglitazone or glipizide on lipoprotein-associated phospholipase A2 in type 2 diabetes

Endocrine Practice

Volumn 13, Issue 2, 2007, Pages 147-152

  Basu, Ananda ^a   Jensen, Michael D ^a   McCann, Frances ^b   Nandy, Debashis ^b   Mukhopadhyay, Debabrata ^b   McConnell, Joseph P ^a   Rizza, Robert A ^a  

^a Mayo Clinic College of Medicine   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GLIPIZIDE; INTERCELLULAR ADHESION MOLECULE 1; LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE A2; LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2; PIOGLITAZONE; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; E-SELECTIN; FEMALE; GLIPIZIDE; HUMANS; HYPOGLYCEMIC AGENTS; INTERCELLULAR ADHESION MOLECULE-1; MALE; MIDDLE AGED; THIAZOLIDINEDIONES; TREATMENT OUTCOME; VASCULAR CELL ADHESION MOLECULE-1;

EID: 34447294272     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.13.2.147     Document Type: Article

References (29)

1. Kota BP, Huang TH, Roufogalis BD. An overview on biological mechanisms of PPARs. Pharmacol Res. 2005;51:85-94.
2. Garg A. Acquired and inherited lipodystrophies. N Engl J Med. 2004;350:1220-1234.
3. Olefsky JM, Saltiel AR. PPAR gamma and the treatment of insulin resistance. Trends Endocrinol Metab. 2000;11: 362-368.
4. Dormandy JA, Charbonnel B, Eckland DJ, et al (PROactive Investigators). Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279-1289.
5. Nishio K, Sakurai M, Kusuyama T, et al. A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes. Diabetes Care. 2006;29:101-106.
6. Marx N, Wohrle J, Nusser T, et al. Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation. 2005;112:2792-2798.
7. Basu A, Jensen MD, McCann F, Mukhopadhyay D, Joyner MJ, Rizza RA. Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes. Diabetes Care. 2006;29: 510-514.
8. Koenig W, Khuseyinova N, Lowel H, Trischler G, Meisinger C. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by Creactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation. 2004;110:1903-1908.
9. Price DT, Loscalzo J. Cellular adhesion molecules and atherogenesis. Am J Med. 1999;107:85-97.
10. Petruzzelli L, Takami M, Humes HD. Structure and function of cell adhesion molecules. Am J Med. 1999;106: 467-476.
11. Hope SA, Meredith IT. Cellular adhesion molecules and cardiovascular disease. Part II. Their association with conventional and emerging risk factors, acute coronary events and cardiovascular risk prediction. Intern Med J. 2003;33:450-462.
12. Hope SA, Meredith IT. Cellular adhesion molecules and cardiovascular disease. Part I. Their expression and role in atherogenesis. Intern Med J. 2003;33:380-386.
13. Ehrhardt C, Kneuer C, Bakowsky U. Selectins - an emerging target for drug delivery. Adv Drug Deliv Rev. 2004; 56:527-549.
14. Wagner OF, Jilma B. Putative role of adhesion molecules in metabolic disorders. Horm Metab Res. 1997;29:627-630.
15. Blake GJ, Ridker PM. Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med. 2002;252: 283-294.
16. Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis. 2003;170:191-203.
17. Boulbou MS, Koukoulis GN, Makri ED, Petinaki EA, Gourgoulianis KI, Germenis AE. Circulating adhesion molecules levels in type 2 diabetes mellitus and hypertension. Int J Cardiol. 2005;98:39-44.
18. Meigs JB, Hu FB, Rifai N, Manson JE. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA. 2004;291:1978-1986.
19. Leinonen E, Hurt-Camejo E, Wiklund O, Hulten LM, Hiukka A, Taskinen MR. Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. Atherosclerosis. 2003;166:387-394.
20. Pasceri V, Wu HD, Willerson JT, Yeh ET. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation. 2000;101:235-238.
21. Imamoto E, Yoshida N, Uchiyama K, et al. Inhibitory effect of pioglitazone on expression of adhesion molecules on neutrophils and endothelial cells. Biofactors. 2004;20: 37-47.
22. Ceriello A, Quagliaro L, Piconi L, et al. Effect of post-prandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes. 2004;53:701-710.
23. Ryysy L, Yki-Jarvinen H. Improvement of glycemic control by 1 year of insulin therapy leads to a sustained decrease in sE-selectin concentrations in type 2 diabetes. Diabetes Care. 2001;24:549-554.
24. Ghanim H, Garg R, Aljada A, et al. Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab. 2001;86:1306-1312.
25. Aljada A, Garg R, Ghanim H, et al. Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action? J Clin Endocrinol Metab. 2001;86:3250-3256.
26. Mohanty P, Aljada A, Ghanim H, et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab. 2004;89:2728-2735.
27. Oei HH, van der Meer IM, Hofman A, et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation. 2005;111:570-575.
28. Serban M, Tanaseanu C, Kosaka T, et al. Significance of platelet-activating factor acetylhydrolase in patients with non-insulin- dependent (type 2) diabetes mellitus. J Cell Mol Med. 2002;6:643-647.
29. Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2004; 109:837-842.